Elanco
ELAN
$22.36
-0.53%
Elanco Animal Health is a global animal health company that develops, manufactures, and markets pharmaceutical products for companion animals and food-producing animals, selling across more than 90 countries with roughly 9,900 employees. The company is a top-tier player in a consolidated animal health oligopoly alongside Zoetis, Merck Animal Health, and Boehringer Ingelheim, with a portfolio spanning pet parasiticides, vaccines, and production-animal therapeutics built through an aggressive acquisition spree (Janssen, Novartis, Boehringer Vetmedica, and Bayer Animal Health) following its 2018 spin-off from Eli Lilly. The current investor narrative centers on a multi-year turnaround: management is deleveraging a balance sheet stretched by the Bayer deal, driving margin expansion through its "Innovation, Portfolio, and Productivity" agenda, and leaning on companion-animal product momentum (notably the Credelio and Zenrelia franchises) to offset a softer food-animal backdrop. Recent headlines highlight Q1 2026 earnings strength, raised guidance, and product momentum, reinforcing the bull case that Elanco is executing on its turnaround — though the stock's persistent underperformance versus the S&P 500 and a still-uneven quarterly earnings record keep the debate alive.…
ELAN
Elanco
$22.36
Related headlines
Investment Opinion: Should I buy ELAN Today?
The synthesized recommendation is Buy, with a one-sentence thesis that Elanco offers an attractive risk/reward for patient investors willing to tolerate volatility, as the market appears to be mispricing a credible turnaround story. The analyst consensus is strong buy with a recommendation mean of 1.5 from 13 analysts, and the average target price of $31.00 implies roughly 40% upside from the current $22.14, while even the lowest target of $26.00 is 17% above the current price. This wide gap between price and targets suggests the market is significantly undervaluing the earnings recovery.
The supporting evidence is compelling: revenue grew 10.23% year-over-year in Q2 2026 to $1.368 billion, gross margin expanded to 58.33% from 46.49% a year earlier, and trailing free cash flow is $379 million (a 3.4% FCF yield). The forward PE of 17.23x is below the S&P 500's typical multiple, and the PEG ratio of 0.28 indicates the stock is cheap relative to projected growth. While the trailing PE is negative due to a Q4 2025 loss, the forward EPS estimate of $1.765 suggests normalized profitability is expected, and the PS ratio of 2.38x is near the low end of its historical range of 3.7x to over 13x.
The biggest risks that could invalidate the thesis are: (1) a failure to sustain margin expansion and revenue growth, which would make the forward estimates unreliable; (2) the heavy debt load with $59 million quarterly interest expense and 1.85x interest coverage, which could force equity dilution or asset sales if earnings disappoint; and (3) competitive pressures from Zoetis and others eroding market share. The rating would upgrade to a stronger Buy if gross margins hold above 55% and revenue growth exceeds 10% for two more quarters, or downgrade to Hold if revenue growth decelerates below 5% or if interest coverage falls below 1.5x. Relative to its history and peers, ELAN appears undervalued on normalized earnings, though the low multiple may reflect legitimate concerns about earnings quality.
Sign up to view all
ELAN 12-Month Price Forecast
The forward-looking view is cautiously bullish, supported by accelerating revenue growth, dramatic gross margin expansion, and a deeply discounted forward valuation. The analyst community is overwhelmingly positive, with a strong buy consensus and a $31.00 average target that implies significant upside, while the absence of sell ratings suggests even bears see limited downside from current levels. However, confidence is tempered by the stock's persistent relative underperformance, thin net margins, and heavy debt burden, which could delay the earnings recovery. The base case (50% probability) assumes steady progress toward $26-$31, while the bull case (30%) and bear case (20%) reflect the wide range of outcomes. I would upgrade to high confidence if Q3 2026 earnings show revenue growth above 10% and net margin above 5%, and downgrade to neutral if revenue growth falls below 5% or if interest coverage deteriorates further.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elanco's 12-month outlook, with a consensus price target around $31.00 and implied upside of +38.6% versus the current price.
Average Target
$31.00
0 analysts
Implied Upside
+38.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$26 - $34
Analyst target range
Coverage is solid with 13 analysts, and sentiment is decisively bullish: the consensus recommendation is "strong_buy" with a recommendation mean of 1.5 (where 1.0 is a strong buy and 5.0 a strong sell). The average target price of $31.00 implies roughly 40% upside from the current price of $22.14 — an unusually large gap that signals analysts believe the market is significantly mispricing the turnaround. Estimated EPS averages $1.765 for the forward period, and estimated revenue averages $6.21 billion, both consistent with a company returning to steady growth and profitability.
The target range spans $26.00 to $34.00, a $8.00 spread (roughly 31% of the low target) that indicates meaningful disagreement about the pace of the recovery. The high target of $34.00 implies multiple expansion toward peer-group levels plus successful execution on margin expansion and debt reduction, while the low target of $26.00 — still 17% above the current price — suggests even the bears see upside, pricing in only modest earnings normalization. Institutional ratings show a stable-to-constructive pattern: UBS, KeyBanc, TD Cowen, Citigroup, JP Morgan, and Leerink all maintain Buy/Overweight/Outperform ratings as of mid-2026, with Morgan Stanley the lone Equal Weight hold. The absence of any Sell ratings and the fact that even the lowest target exceeds the current price is a powerful signal that the analyst community views the recent sell-off as an opportunity rather than a warning.
Drowning in data?
Find the real signal!
Bulls vs Bears: ELAN Investment Factors
The bull case currently has stronger evidence, anchored by accelerating revenue growth of 10.23% year-over-year, a dramatic 1,190 basis point gross margin expansion to 58.33%, and a unanimous strong buy analyst consensus with a $31.00 average target implying 40% upside. However, the bear case is not without merit: the stock's persistent relative underperformance (-21.42 percentage points versus SPY over six months), thin net margins of 3.95%, and heavy $59 million quarterly interest expense highlight real execution and financial risks. The single most important tension is whether the margin expansion and revenue reacceleration are sustainable and can translate into consistent GAAP profitability, or whether the Q4 2025 loss and lumpy cash generation are signs of deeper earnings-quality issues. If the turnaround proves durable, the low forward PE of 17.23x and PEG of 0.28 suggest significant upside; if it stalls, the high beta and elevated short interest could accelerate downside toward the 52-week low.
Bullish
- Revenue reaccelerating at double digits: Q2 2026 revenue of $1.368 billion grew 10.23% year-over-year, a sharp acceleration from the $1.241 billion in Q2 2025 and the $1.137 billion trough in Q3 2025. The sequential trend is constructive, with Q1 2026 at $1.371 billion and Q2 2026 at $1.368 billion, both well above the $1.144 billion Q4 2025 low. If sustained, this supports the consensus revenue estimate of roughly $6.21 billion.
- Gross margin expanded to 58.33%: Q2 2026 gross margin of 58.33% represents a substantial expansion from 46.49% in Q2 2025 and 39.34% in Q4 2025. This 1,190 basis point year-over-year improvement signals successful execution on the Innovation, Portfolio, and Productivity agenda and operating leverage as revenue scales.
- Analyst consensus strong buy with 40% upside: All 13 covering analysts rate ELAN a strong buy (recommendation mean of 1.5), with an average target price of $31.00 implying roughly 40% upside from the current $22.14. Even the lowest target of $26.00 sits 17% above the current price, and there are zero sell ratings, indicating the analyst community views the sell-off as an opportunity.
- Forward PE of 17.23x is undemanding: While trailing PE is meaningless due to negative trailing EPS of -$0.02, the forward PE of 17.23x based on 2027 EPS estimates of $1.765 is below the S&P 500's typical forward multiple. The PEG ratio of 0.28 further suggests the stock is cheap relative to projected growth, implying significant multiple expansion potential if earnings normalize.
Bearish
- Persistent relative underperformance: ELAN trails SPY by 10.88 percentage points over one month, 14.78 points over three months, and 21.42 points over six months, indicating active capital rotation away from the name. The stock is down 10.29% over the past month and 11.44% over three months, versus an 8.16% one-year gain, signaling a stalled rally being unwound.
- Thin and volatile profitability: Q2 2026 net income was only $54 million on a 3.95% net margin, and the trailing picture is muddied by a $276 million net loss in Q4 2025 (a -24.13% net margin quarter). Trailing net margin is -4.92% and trailing EPS is -$0.02, with ROE negative at -3.54%, highlighting earnings quality concerns.
- Heavy interest burden limits flexibility: Quarterly interest expense of $59 million consumes a large share of operating income, with interest coverage of roughly 1.85x leaving limited margin for error. This debt load, a legacy of the Bayer Animal Health acquisition, constrains reinvestment capacity and exposes earnings to rate fluctuations.
- High volatility and wide drawdowns: Beta of 1.677 means ELAN is roughly 68% more volatile than the S&P 500, and the -26.23% max drawdown underscores how punishing pullbacks have been. The wide 52-week band of $19.40 to $27.98 (a 44% spread) reinforces that this is a high-risk, catalyst-driven name requiring smaller position sizing.
ELAN Technical Analysis
Elanco is in a choppy, range-bound consolidation rather than a clean trend, with the shares up 8.16% over the past year but down 1.69% year-to-date and 4.07% over six months. At a current price of $22.14, the stock sits at roughly 32% of its 52-week range of $19.40 to $27.98 — closer to the lower end than the middle, which signals neither momentum leadership nor a deep-value falling knife, but rather a market that has lost conviction after a failed rally attempt. The 1-year gain of 8.16% masks a wide round-trip: the stock ran to nearly $28 before retreating, and the -26.23% max drawdown underscores how punishing the pullbacks have been for holders.
Short-term momentum has deteriorated sharply and is diverging negatively from the longer-term trend. The stock is down 10.29% over the past month and 11.44% over three months, versus a 1-year gain of 8.16% — a clear deceleration that suggests the late-2025/early-2026 advance has stalled and is being unwound. Relative strength confirms the weakness: ELAN trails SPY by 10.88 percentage points over one month, 14.78 points over three months, and 21.42 points over six months, meaning capital is actively rotating away from the name. The most recent session did show a modest bounce (+1.70% on the day, from $21.77 to $22.14), but with a short ratio of 6.45, elevated short interest could amplify either a squeeze or further downside.
Key technical levels are well defined: support sits at the 52-week low of $19.40, roughly 12% below the current price, while resistance is the 52-week high of $27.98, about 26% above. A decisive break below $19.40 would signal a resumption of the downtrend and likely invite momentum sellers, whereas reclaiming the mid-$24s and then $27.98 would confirm a new leg higher. Volatility is a critical consideration — the beta of 1.677 means ELAN is roughly 68% more volatile than the S&P 500, so position sizing should be materially smaller than a market-weight allocation, and the wide 52-week band ($19.40–$27.98, a 44% spread) reinforces that this is a high-risk, catalyst-driven name.
Beta
1.71
1.71x market volatility
Max Drawdown
-26.2%
Largest decline past year
52-Week Range
$19-$28
Price range past year
Annual Return
+9.3%
Cumulative gain past year
| Period | ELAN Return | S&P 500 |
|---|---|---|
| 1m | -8.7% | +0.9% |
| 3m | -9.2% | +3.4% |
| 6m | -3.3% | +14.4% |
| 1y | +9.3% | +16.2% |
| ytd | -0.7% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELAN Fundamental Analysis
Elanco's revenue trajectory has reaccelerated meaningfully. Q2 2026 revenue came in at $1.368 billion, up 10.23% year-over-year, a sharp improvement from the $1.241 billion reported in Q2 2025 and the $1.137 billion in Q3 2025. The sequential trend is constructive — Q1 2026 revenue of $1.371 billion and Q2 2026 of $1.368 billion are both well above the $1.144 billion trough in Q4 2025 — and the segment mix shows Pet Health at $718 million and Farm Animal at $633 million as the twin growth engines, with Cattle ($313 million), Poultry ($223 million), Swine ($97 million), and Contract Manufacturing ($17 million) rounding out the portfolio. The 10%+ growth rate, if sustained, supports the consensus revenue estimate of roughly $6.21 billion and validates the product-momentum narrative.
Profitability is improving but remains thin and volatile. Q2 2026 net income was $54 million on a 3.95% net margin, with gross margin of 58.33% — a substantial expansion from the 46.49% gross margin in Q2 2025 and the 39.34% in Q4 2025. However, the trailing picture is muddied by a $276 million net loss in Q4 2025 (a -24.13% net margin quarter driven by impairments and other charges), which drags the trailing net margin to -4.92% and trailing EPS to -$0.02. Operating margin of 5.34% and EBITDA margin of 20.03% in Q2 2026 show the underlying business is profitable at the operating line, but interest expense of $59 million per quarter remains a heavy burden that consumes a large share of operating income.
Balance sheet health is adequate but not fortress-like. Debt-to-equity stands at 0.61, the current ratio is a healthy 2.17, and trailing free cash flow is $379 million — a solid 3.4% FCF yield on the $11.23 billion market cap. Q2 2026 free cash flow was $244 million on operating cash flow of $277 million, though Q1 2026 FCF was negative $38 million due to a $263 million working-capital drag, highlighting the seasonality and lumpiness of cash generation. ROE is negative at -3.54% on a trailing basis (reflecting the Q4 2025 loss), while ROA is a positive 1.56%; the company is funding capex ($33 million in Q2 2026) and small bolt-on acquisitions ($76 million) internally, but the debt load and interest coverage of roughly 1.85x leave limited margin for error if earnings disappoint.
Quarterly Revenue
$1.4B
2026-06
Revenue YoY Growth
+10.2%
YoY Comparison
Gross Margin
58.3%
Latest Quarter
Free Cash Flow
$379000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELAN Overvalued?
Because Elanco's trailing net income is negative (trailing EPS of -$0.02, trailing PE of -48.15x), the PE ratio is not meaningful as a primary metric; instead, the PS ratio of 2.38x and EV/Sales of 2.90x are the appropriate anchors, supplemented by the forward PE of 17.23x, which reflects the market's expectation that earnings will normalize. The gap between the meaningless trailing PE and the 17.23x forward PE is the key signal: the market is pricing in a sharp earnings recovery, consistent with the consensus 2027 EPS estimate of $1.765. On EV/EBITDA of 21.75x, the stock looks expensive relative to its own history, though this multiple is distorted by the depressed trailing EBITDA base.
Relative to the broader Drug Manufacturers - Specialty & Generic industry, Elanco's 2.38x PS and 2.90x EV/Sales sit at a premium to many generic-oriented peers but at a discount to premium animal-health leader Zoetis, which historically trades at a significant multiple premium. The forward PE of 17.23x is arguably the most telling comparison — it is below the S&P 500's typical forward multiple and below many healthcare peers, suggesting that if the earnings recovery materializes, ELAN is not expensively valued on normalized earnings. The PEG ratio of 0.28 (based on forward growth expectations) further supports the view that the stock is cheap relative to its projected growth rate, though this metric is highly sensitive to the reliability of the growth estimate.
Historically, Elanco's PS ratio has ranged from roughly 3.7x (Q1 2023) to over 13x (Q3 2021), and its price-to-book has ranged from about 0.62x (Q1 2023) to 2.02x (Q3 2021). At the current PS of 2.38x and P/B of 1.72x, the stock is trading near the low end of its multi-year valuation band — a level that historically has coincided with pessimism and potential value opportunities, but also with periods of genuine fundamental deterioration. The market is clearly not pricing in optimistic expectations at these levels; the risk is that the low multiple reflects real earnings-quality concerns rather than an inefficiency.
PE
-48.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~65x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.8x
Enterprise Value Multiple
Investment Risk Disclosure
Elanco's financial and operational risks are substantial and quantifiable. The company carries a debt-to-equity ratio of 0.61 with quarterly interest expense of $59 million, resulting in interest coverage of roughly 1.85x, which leaves little cushion if EBITDA declines. Profitability is thin and volatile: Q2 2026 net margin was just 3.95%, and the trailing net margin is -4.92% due to a $276 million net loss in Q4 2025, while trailing EPS is -$0.02 and ROE is -3.54%. Revenue concentration is moderate, with Pet Health at $718 million and Farm Animal at $633 million in Q2 2026, but the food-animal segment faces softer market conditions, and the company's aggressive acquisition history has created integration and impairment risks, as evidenced by the Q4 2025 charges.
Market and competitive risks are amplified by Elanco's premium valuation relative to its own history and its high beta. The stock trades at a PS ratio of 2.38x and EV/Sales of 2.90x, which is a premium to many generic-oriented peers but a discount to Zoetis; however, the EV/EBITDA of 21.75x looks expensive on a depressed trailing EBITDA base. With a beta of 1.677, ELAN is roughly 68% more volatile than the S&P 500, making it highly sensitive to macro risk-off episodes and sector rotation. Competitive threats from Zoetis, Merck Animal Health, and Boehringer Ingelheim are persistent, and the recent news of Q1 2026 earnings strength and raised guidance has not prevented a 10.29% one-month decline, suggesting the market is skeptical of the durability of the turnaround.
The worst-case scenario would involve a stall in revenue growth, margin compression from competitive pressure or input costs, and a failure to deleverage, leading to earnings misses and analyst downgrades. In this scenario, the stock could retest its 52-week low of $19.40, representing a decline of approximately 12.4% from the current price of $22.14. A more severe outcome, such as a recession that hits pet spending and farm animal demand simultaneously, could push the stock below the 52-week low toward the analyst low target of $26.00 (which is above current price, so the downside is better framed by the 52-week low and the -26.23% max drawdown). From the current price, a drop to $19.40 would mean a loss of about 12.4%, and if the stock revisits its max drawdown level of -26.23% from a recent high, the downside could be more severe. Investors should note that the absence of a dividend (payout ratio of 0) means total return depends entirely on price appreciation.
FAQ
The most severe risk is financial: quarterly interest expense of $59 million and interest coverage of roughly 1.85x leave little margin for error, and a decline in EBITDA could pressure the balance sheet. Second, operational risk: profitability is thin and volatile, with a trailing net margin of -4.92% and a $276 million loss in Q4 2025, so any revenue miss could quickly turn earnings negative. Third, competitive risk: Elanco faces formidable rivals in Zoetis, Merck Animal Health, and Boehringer Ingelheim, and market-share losses in key products like Credelio could derail growth. Fourth, market risk: the high beta of 1.677 means ELAN is 68% more volatile than the S&P 500, and a macro downturn could disproportionately hit the stock, especially given its 21.42 percentage point underperformance versus SPY over six months.
The 12-month forecast is based on three scenarios: a base case (50% probability) targeting $26-$31, assuming steady high-single-digit revenue growth and stable margins; a bull case (30% probability) targeting $31-$34, driven by sustained 10%+ growth and margin expansion; and a bear case (20% probability) targeting $19.40-$26, if growth stalls and margins compress. The most likely scenario is the base case, which assumes revenue growth moderates to 7-9% and gross margins hold around 55-58%, allowing the stock to gradually re-rate toward the analyst average target of $31.00. Key assumptions include no major macro shocks, continued companion-animal momentum, and successful deleveraging. The wide target range reflects the high uncertainty inherent in a turnaround story.
ELAN appears undervalued on normalized earnings but carries a premium on some trailing metrics. The trailing PE is not meaningful due to negative EPS, but the forward PE of 17.23x is below the S&P 500's typical multiple, and the PEG ratio of 0.28 indicates the stock is cheap relative to projected growth. The PS ratio of 2.38x is near the low end of its historical range of 3.7x to over 13x, suggesting the market is pricing in pessimism. However, the EV/EBITDA of 21.75x looks expensive on a depressed trailing EBITDA base, and the P/B of 1.72x is above the historical low of 0.62x. Overall, the market seems to be paying a fair-to-discount price for a company with improving fundamentals, implying it expects the earnings recovery to materialize but is not yet giving full credit.
From a risk/reward perspective, ELAN presents an attractive but volatile opportunity. The stock trades at $22.14, with analysts' average target of $31.00 implying roughly 40% upside, and even the lowest target of $26.00 is 17% above the current price. The forward PE of 17.23x and PEG of 0.28 suggest the stock is cheap relative to its growth prospects, while revenue growth of 10.23% and gross margin expansion to 58.33% support the turnaround narrative. However, the biggest downside risk is a retest of the 52-week low of $19.40, which would represent a 12.4% loss, and the high beta of 1.677 means the stock can swing widely. It is a good buy for patient investors with a high risk tolerance who believe in the multi-year margin recovery, but it is not suitable for those seeking stability or income.
ELAN is better suited for long-term investment than short-term trading, given its high volatility and the multi-year nature of its turnaround. The beta of 1.677 and max drawdown of -26.23% make it risky for short-term traders, while the absence of a dividend means total return depends on price appreciation. The company is in a growth-and-recovery phase, with earnings visibility still limited due to lumpy quarterly results, so a minimum holding period of 2-3 years is advisable to allow the margin expansion and deleveraging to play out. Short-term traders might exploit the wide 52-week range of $19.40 to $27.98, but they should use tight stop-losses given the elevated short ratio of 6.45 and potential for sharp moves.
